|
Liver carcinoma
|
0.400 |
Biomarker
|
disease |
CTD_human |
Gene expression patterns in HCCs from Myc, E2f1 and Myc E2f1 transgenic mice were most similar to those of the better survival group of human HCCs, whereas the expression patterns in HCCs from Myc Tgfa transgenic mice and in diethylnitrosamine-induced mouse HCCs were most similar to those of the poorer survival group of human HCCs.
|
15565109 |
2004 |
|
Liver carcinoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Upregulation of E2F1 and STMN1 proteins associate with worse outcomes in patients with HCC.
|
22911364 |
2013 |
|
Liver carcinoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Highest total and phosphorylated protein levels of MYBL2, E2F1-DP1, inactivated retinoblastoma protein (pRB), and cyclin B1 occurred in HCC with poorer outcome (HCCP), compared to HCC with better outcome (HCCB).
|
21480327 |
2011 |
|
Liver carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
The pathway analyses of the miRNA-mRNA co-modules identified by the algorithm demonstrate key roles of Myc, E2F1, let-7, TGFB1, TNF and EGFR in HCC subgroups.
|
24223834 |
2013 |
|
Liver carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Impairment of the Pin1/E2F1 axis in the anti-proliferative effect of bortezomib in hepatocellular carcinoma cells.
|
25742740 |
2015 |
|
Liver carcinoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
E2F1, the most extensively studied member and the only one with prognostic value, exhibits a tumor-suppressing activity in esophageal, gastric and colorectal adenocarcinoma, and in hepatocellular carcinoma (HCC), whereas in pancreatic ductal adenocarcinoma and esophageal squamous cell carcinoma may function as a tumor-promoter.
|
23745020 |
2013 |
|
Liver carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
PHEA-DETA-PEG-GAL has suitable chemical-physical characteristics for a potential systemic use and can effectively deliver a siRNA (siE2F1) targeted against the transcription factor E2F1, a gene product involved in HCC.
|
28119125 |
2017 |
|
Liver carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
The data available so far indicate that the proliferative and apoptotic functions of E2F1 in HCC may coexist but the proliferative effect seems to be more pronounced than the apoptotic one.
|
27109336 |
2017 |
|
Liver carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Cyclin D1, E2F transcription factor 1, epithelial growth factor receptor, MYC, MET proto-oncogene, receptor tyrosine kinase and vascular endothelial growth factor A were identified as target genes for the HCC progression, two of which were also the target genes of hsa-miR-1 and hsa-miR-20a-5p using the miRwalk and OncoDN.HCC databases.
|
29740493 |
2018 |
|
Liver carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Highest Mybl2, Clusterin, Cdc2, and Cyclin B1 expression occurred in fast progressing DN and HCC of E2f1 transgenics, compared to c-Myc transgenics, and anti-Mybl2 siRNA had highest anti-proliferative and apoptogenic effects in cell lines from HCC of E2f1 transgenics.
|
21419759 |
2011 |
|
Liver carcinoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Importantly, human hepatocellular carcinomas (HCCs) recapitulate POH1 regulation of E2F1 expression, as nuclear abundance of POH1 is increased in HCCs and correlates with E2F1 overexpression and tumour growth.
|
26510456 |
2015 |
|
Liver carcinoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Overexpression of miR-34a promoted MICB expression in hepatocytes and hepatocellular carcinoma (HCC) cells that have low E2F1 levels but not in HCC cells that have high E2F1 levels.
|
30256916 |
2018 |
|
Liver carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Hypoxia inducible factor 2 alpha inhibits hepatocellular carcinoma growth through the transcription factor dimerization partner 3/ E2F transcription factor 1-dependent apoptotic pathway.
|
23212661 |
2013 |
|
Liver carcinoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
In the present study, upregulation of SET7/9 and E2F transcription factor 1 (E2F1) expression was detected in 68 samples of HCC tissues compared with these levels noted in the paired healthy liver samples.
|
30106440 |
2018 |
|
Liver carcinoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
The tumor suppressive effect of AdhTERT-E2F therapy was further enhanced in combination with IFNalpha.Our results demonstrate that PKR activating agents enhance the anti-tumor effect of E2F-1 overexpression in HCC in-vitro and in-vivo.
|
18535617 |
2008 |
|
Liver carcinoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Hepatitis B Virus X Protein Upregulates hELG1/ ATAD5 Expression through E2F1 in Hepatocellular Carcinoma.
|
26722215 |
2016 |
|
Liver carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Our data provide novel mutual relationships amongst cyclin E1-E2-E2F1 and indicate their role in sustaining hepatocellular carcinoma cell proliferation/migration, validating the concept of an anti-cyclin E1-E2-E2F1 therapeutic approach for hepatocellular carcinoma.
|
21831731 |
2011 |
|
Liver carcinoma
|
0.400 |
Biomarker
|
disease |
CTD_human |
In nodules and/or HCCs of Wistar and BN rats, low or no increases in c-myc, Cyclins D1, E, and A, and E2F1 expression, and Cyclin-CDKs complex formation were associated with p16(INK4A) overexpression and pRb hypophosphorylation.
|
12029619 |
2002 |
|
Liver carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
In summary, our results suggested that aflatoxin B1 could promote cell growth and invasion in hepatocellular carcinoma HepG2 cells through actions on H19 and E2F1.
|
24761865 |
2014 |
|
Liver carcinoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Moreover, functional tests revealed that the G1/G0 block induced by eEF1A1 depletion depends on the down-regulation of the transcription factor E2F1, a known player in HCC.
|
28229942 |
2017 |
|
Liver carcinoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
HBV CP mutations enhance SKP2 transcription by activating the E2F1 transcription factor and in turn downregulate cell cycle inhibitors, thus providing a potential mechanism for an association between CP mutations and HCC.
|
23348237 |
2013 |
|
Liver carcinoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
We recently reported that the expression of dbpA (DNA binding protein A) is associated with advanced stages of human hepatocellular carcinoma (HCC) and that its transcription is positively regulated by E2F1, which is also implicated in hepatocarcinogenesis.
|
16865284 |
2006 |
|
Liver carcinoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Gene expression patterns in HCCs from Myc, E2f1 and Myc E2f1 transgenic mice were most similar to those of the better survival group of human HCCs, whereas the expression patterns in HCCs from Myc Tgfa transgenic mice and in diethylnitrosamine-induced mouse HCCs were most similar to those of the poorer survival group of human HCCs.
|
15565109 |
2004 |
|
Liver carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Analysis of regulatory networks for HBV HCC revealed E2F1 as activated UR, regulating genes involved in cell cycle and DNA replication, and HNF4A and HNF1A as inhibited UR.
|
29672926 |
2018 |
|
Liver carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
<b>Results:</b> E2F1 with its surrounding regulatory links were identified to play different key roles in the HCC risk factor dysregulation mechanisms.
|
31729887 |
2019 |